Alzheimer's disease plasma biomarkers in a global cohort: experience from the DAWN study

Abstract Background The DAWN study aims to investigate Alzheimer's disease (AD) genetics and underlying biological markers in a global population including African Americans (AA: 4,000) and Hispanic/Latinos (HI: 4,000) ascertained in the US and indigenous Africans (AF: 5,000) through collaboration with the African Dementia Consortium (AfDC) from 10 African counties. These 13,000 participants include AD cases and individuals with mild (MCI) or no cognitive impairment (NCI). To understand the underlying blood‐based AD biomarkers profile of this unique cohort, we are analyzing the plasma levels of pTau181, neurofilament light chain (NFL), and Glial fibrillary acidic protein (GFAP). Method We measured pTau181 and NFL, and GFAP with Simoa chemistry using the pTau181 AdvantageV2 and NEUROLOGY 4‐PLEX A assays, respectively, on the Quanterix HD‐X instrument. Our preliminary cohort consisted of 174 AF (86 AD; 88 NCI) from Nigeria and Ghana study sites, 254 AA (24 AD; 102 MCI; 85 NCI), and 166 HI (44 AD; 61 MCI; 62 NCI). Linear mixed‐effect regression models adjusted for age, sex, population substructure and relatedness followed by Bonferroni correction were applied to identify biomarker differences. Result There were no significant differences between the ancestral groups within the diagnostic categories for any of the biomarkers measured. Plasma pTau181 concentrations were increased in AD relative to NCI in all three populations ( p = 5.1x10 ‐4 , 9.6x10 ‐5 , 5.1x10‐4 in AA, AF, and HI respectively) and AD relative to MCI ( p = 0.012, 0.0014 in AA and HI respectively), though no differences were noted between MCI and NCI. Interestingly, GFAP and NFL were highly significantly increased in AF AD vs NCI ( p = 4.5x10 ‐9 , 7.9x10 ‐7 for GFAP and NFL respectively) and in HI ( p = 7.9x10 ‐8 , 1.6x10 ‐6 for GFAP and NFL respectively), but no differences noted in AA. Conclusion These results suggest AD biomarkers are generalizable across global populations, with baseline values being consistent. However, there are notable differences, particularly in NFL and GFAP levels, which may reflect underlying differences in environmental or genetic influences on AD. Ultimately, increasing sample sizes and combining genomic, biomarker, and social and environmental data will increase understanding of genetic risk of AD.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70856_105522
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Alzheimer's disease plasma biomarkers in a global cohort: experience from the DAWN study

Giuseppe Tosto, Scott M. Williams, Patrice Whitehead, Michael Cuccaro et al.
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
article

Alzheimer's disease plasma biomarkers in a global cohort: experience from the DAWN study

Giuseppe Tosto, Scott M. Williams, Patrice Whitehead, Michael Cuccaro, Alfred K. Njamnshi, Stella‐Maria Paddick, Joshua Odunayo Akinyemi, Seid Ali Gugssa, Rufus Akinyemi, Samuel Diala, Susan H. Blanton, Mayowa Ogunronbi, Kara L. Hamilton‐Nelson, Kazeem Akinwande, Christiane Reitz, Kyle Scott, Reginald Obiako, William S. Bush, Albert Akpalu, Yared Z. Zewde, Pedro Mena, Njideka Okubadejo, Anthony J. Griswold, Jacob Lee McCauley, D. M. Ndetei, Biniyam Ayele, Raj N Kalaria, Katalina McInerney, Izri M Martinez, Andrew F Zaman, Margaret Pericak‐Vance, Allison M Caban‐Holt, Kolawole Wahab, Jonathan L Haines, Richard Walker, Maëlenn Guerchet, Olusegun Baiyewu, Larry D Adams, Farid Rajabli, Goldie S Byrd, Sudha Seshadri, Albertino Damasceno, Adesola Ogunniyi, Brian W Kunkle, Fred Stephen Sarfo, Jeffery M Vance, Motunrayo Coker
article en

Abstract

Abstract Background The DAWN study aims to investigate Alzheimer's disease (AD) genetics and underlying biological markers in a global population including African Americans (AA: 4,000) and Hispanic/Latinos (HI: 4,000) ascertained in the US and indigenous Africans (AF: 5,000) through collaboration with the African Dementia Consortium (AfDC) from 10 African counties. These 13,000 participants include AD cases and individuals with mild (MCI) or no cognitive impairment (NCI). To understand the underlying blood‐based AD biomarkers profile of this unique cohort, we are analyzing the plasma levels of pTau181, neurofilament light chain (NFL), and Glial fibrillary acidic protein (GFAP). Method We measured pTau181 and NFL, and GFAP with Simoa chemistry using the pTau181 AdvantageV2 and NEUROLOGY 4‐PLEX A assays, respectively, on the Quanterix HD‐X instrument. Our preliminary cohort consisted of 174 AF (86 AD; 88 NCI) from Nigeria and Ghana study sites, 254 AA (24 AD; 102 MCI; 85 NCI), and 166 HI (44 AD; 61 MCI; 62 NCI). Linear mixed‐effect regression models adjusted for age, sex, population substructure and relatedness followed by Bonferroni correction were applied to identify biomarker differences. Result There were no significant differences between the ancestral groups within the diagnostic categories for any of the biomarkers measured. Plasma pTau181 concentrations were increased in AD relative to NCI in all three populations ( p = 5.1x10 ‐4 , 9.6x10 ‐5 , 5.1x10‐4 in AA, AF, and HI respectively) and AD relative to MCI ( p = 0.012, 0.0014 in AA and HI respectively), though no differences were noted between MCI and NCI. Interestingly, GFAP and NFL were highly significantly increased in AF AD vs NCI ( p = 4.5x10 ‐9 , 7.9x10 ‐7 for GFAP and NFL respectively) and in HI ( p = 7.9x10 ‐8 , 1.6x10 ‐6 for GFAP and NFL respectively), but no differences noted in AA. Conclusion These results suggest AD biomarkers are generalizable across global populations, with baseline values being consistent. However, there are notable differences, particularly in NFL and GFAP levels, which may reflect underlying differences in environmental or genetic influences on AD. Ultimately, increasing sample sizes and combining genomic, biomarker, and social and environmental data will increase understanding of genetic risk of AD.

Alzheimer s & DementiaVol. 21(S2)
Ahmadu Bello University (NG), University of Nairobi (KE), Université de Yaoundé I (CM), University of Ilorin (NG), University of Ghana (GH), University of Miami (US), The University of Texas at San Antonio Health Science Center (US), Eduardo Mondlane University (MZ), University of Ibadan (NG), University of Lagos (NG), Kwame Nkrumah University of Science and Technology (GH), Gateshead Health NHS Foundation Trust (GB), Institute for Neurodegenerative Disorders (US), The Neurosciences Foundation (GB), Université d'Abomey-Calavi (BJ), Dr. John T. Macdonald Foundation (US), Catholic University of Central Africa (CM), University of Ilorin Teaching Hospital (NG), University School (US), Global Brain Health Institute (US), Addis Ababa University (ET), Wake Forest University (US), Case Western Reserve University (US), Columbia University (US), Newcastle University (GB)
Openalex Percentile: Top 29%
Dementia and Cognitive Impairment Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.